Key result
APOC3 and ANGPTL3 inhibitors near clinical use to reduce triglycerides and potentially lower cardiovascular events.
Why the study?
Driven by genetic cohort studies showing a link between circulating triglycerides and cardiovascular events, inhibitors of APOC3 and ANGPTL3 are poised to enter clinical practice.
Therapies targeting APOC3 and ANGPTL3 are emerging as novel approaches to treat dyslipidemia by reducing circulating triglycerides.
The positive relationship between increased levels of circulating triglycerides and cardiovascular events has been observed for decades. Driven by genetic cohort studies, inhibitors of APOC3 (apolipoprotein C3) and ANGPTL (angiopoietin-like protein) 3 that reduce circulating triglycerides are poised to enter clinical practice. We will review the biology of how inhibition of these 2 proteins affects circulating lipoproteins as well as the current state of clinical development of monoclonal antibodies, antisense oligonucleotides, and silencing RNAs targeting APOC3 and ANGPTL3.
No takes yet. Share an insight, caveat, or question.
Ginsberg et al. (2022) conducted a review in Dyslipidemia. APOC3 and ANGPTL3 inhibitors was evaluated. Inhibitors of APOC3 and ANGPTL3 are poised to enter clinical practice to reduce circulating triglycerides and potentially lower cardiovascular events.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: